ImmunityBio, Inc. (IBRX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 10.50B USD. 52-week range 1.95 to 12.43 USD. Data as of 2026-10-09.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are ...